<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31682085</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2384</StartPage><EndPage>2394</EndPage><MedlinePgn>2384-2394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.50930</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mutations in Fused in Sarcoma (FUS or TLS) are the fourth most prevalent in Western European familial amyotrophic lateral sclerosis (ALS) populations and have been associated with causing both early and very late disease onset. FUS aggregation, DNA repair deficiency, and genomic instability are contributors to the pathophysiology of FUS-ALS, but their clinical significance per se and their influence on the clinical variability have yet to be sufficiently investigated. The aim of this study was to analyze genotype-phenotype correlations and malignancy rates in a newly compiled FUS-ALS cohort.</AbstractText><AbstractText Label="METHODS">We cross-sectionally reviewed FUS-ALS patient histories in a multicenter cohort with 36 novel cases and did a meta-analysis of published FUS-ALS cases reporting the largest genotype-phenotype correlation of FUS-ALS.</AbstractText><AbstractText Label="RESULTS">The age of onset (median 39&#xa0;years, range 11-80) was positively correlated with the disease duration. C-terminal domain mutations were found in 90%. Among all, P525L and truncating/ frameshift mutations most frequently caused juvenile onset, rapid disease progression, and atypical ALS often associated with negative family history while the R521 mutation site was associated with late disease onset and pure spinal phenotype. Malignancies were found in one of 40 patients.</AbstractText><AbstractText Label="INTERPRETATION">We report the largest genotype-phenotype correlation of FUS-ALS, which enables a careful prediction of the clinical course in newly diagnosed patients. In this cohort, FUS-ALS patients did not have an increased risk for malignant diseases.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2431-5843</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, 18147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peikert</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, 18147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Kooi</LastName><ForeName>Anneke J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amsterdam UMC, Academic Medical Centre, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, Department of (Neuro)Pathology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xfc;bers</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, German Center for Neurodegenerative Diseases, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danel</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre expert pour la SLA et les maladies du motoneurone h&#xf4;pital SALENGRO, CHU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre expert pour la SLA et les maladies du motoneurone h&#xf4;pital SALENGRO, CHU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan-Montojo</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum der Universit&#xe4;t M&#xfc;nchen, Munich Cluster for Systems Neurology, SyNergy, Munich, 81377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirak</LastName><ForeName>Sebahattin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pediatric Neurology, Department of Pediatrics, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Molecular Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haliloglu</LastName><ForeName>G&#xf6;knur</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatric Neurology, Hacettepe University Children's Hospital, Ankara, 06100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, German Center for Neurodegenerative Diseases, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Anand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, 3052074, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, SE-90185, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudlo</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, 18147, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, 18147, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegner</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Neuroscience, VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, German Center for Neurodegenerative Diseases, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7364-7791</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, 18147, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, 18147, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, Rostock, 18147, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Swedish non-for profit patient organization Neuroforbundet</Agency><Country>International</Country></Grant><Grant><Agency>Swedish Research Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Hermann und Lilly Schilling-Stiftung f&#xfc;r medizinische Forschung im Stifterverband</Agency><Country>International</Country></Grant><Grant><Agency>KU Leuven funds "Een Hart voor ALS" and "Laeversfonds voor ALS Onderzoek"</Agency><Country>International</Country></Grant><Grant><Agency>Knut och Alice Wallenbergs Stiftelse</Agency><Country>International</Country></Grant><Grant><GrantID>CI 218/1-1</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country>International</Country></Grant><Grant><Agency>Else-Kr&#xf6;ner-Forschungskolleg Dresden</Agency><Country>International</Country></Grant><Grant><Agency>FWO-Vlaanderen</Agency><Country>International</Country></Grant><Grant><Agency>ALS Liga Belgi&#xeb;</Agency><Country>International</Country></Grant><Grant><GrantID>VH-VI-510</GrantID><Agency>Helmholtz Virtual Institute "RNA dysmetabolism in ALS and FTD</Agency><Country>International</Country></Grant><Grant><Agency>Swedish Research Council</Agency><Country>International</Country></Grant><Grant><Agency>Stiftung zur F&#xf6;rderung der Hochschulmedizin in Dresden</Agency><Country>International</Country></Grant><Grant><Agency>NOMIS Stiftung</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31682085</ArticleId><ArticleId IdType="pmc">PMC6917314</ArticleId><ArticleId IdType="doi">10.1002/acn3.50930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89:817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S, Neumann M, Rosenbohm A, et al. Truncating mutations in FUS/TLS give rise to a more aggressive ALS&#x2010;phenotype than missense mutations: a clinico&#x2010;genetic study in Germany. Eur J Neurol 2013;20:540&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A, Just W, Rosenbohm A, et al. De novo FUS mutations are the most frequent genetic cause in early&#x2010;onset German ALS patients. Neurobiol Aging 2015;36:1&#x2013;3117.</Citation><ArticleIdList><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A, Lattante S, Zollino M, et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul Disord 2012;22:73&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T, Warita H, Kato M, et al. Genotype&#x2010;phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan. Muscle Nerve 2016;54:398&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">26823199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population&#x2010;based study. Neurology 2002;59:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 2013;34:812&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Huang EJ. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res 2016;15:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Lemay N, Ko HK, et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet 2010;19:4160&#x2013;4175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier&#x2010;Tourenne C, Polymenidou M, Cleveland DW. TDP&#x2010;43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010;19(R1):R46&#x2013;R64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Pal A, Goswami A, et al. Impaired DNA damage response signaling by FUS&#x2010;NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat Commun 2018;9:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H, Lee S, Shang Y, et al. ALS&#x2010;associated mutation FUS&#x2010;R521C causes DNA damage and RNA splicing defects. J Clin Invest 2014;124:981&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938263</ArticleId><ArticleId IdType="pubmed">24509083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, Pan L, Su SC, et al. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat Neurosci 2013;16:1383&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564396</ArticleId><ArticleId IdType="pubmed">24036913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks GG, Singh N, Nashabi A, et al. Fus deficiency in mice results in defective B&#x2010;lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 2000;24:175&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda M, Sok J, Webb L, et al. Male sterility and enhanced radiation sensitivity in TLS(&#x2010;/&#x2010;) mice. EMBO J 2000;19:453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305582</ArticleId><ArticleId IdType="pubmed">10654943</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta&#x2010;analysis. Cancer Causes Control 2010;21:697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">20054708</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver JA, Beiser A, Au R, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 2012;344:e1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647385</ArticleId><ArticleId IdType="pubmed">22411920</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Al&#x2010;Chalabi A, Ronnevi LO, et al. Amyotrophic lateral sclerosis and cancer: a register&#x2010;based study in Sweden. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:362&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451142</ArticleId><ArticleId IdType="pubmed">23527497</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland J, Bertz J, Wolf U, et al. German cancer statistics 2004. BMC Cancer 2010;22:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837012</ArticleId><ArticleId IdType="pubmed">20175882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 2009;10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Peter RS, Erhardt S, et al. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol 2017;264:749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J, Demestre M, Putz S, et al. FUS mislocalization and vulnerability to DNA damage in ALS patients derived hiPSCs and aging motoneurons. Front Cell Neurosci 2016;10:290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5183648</ArticleId><ArticleId IdType="pubmed">28082870</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Danel V, Lacour A, et al. A novel mutation of the C&#x2010;terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:298&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji J, Sundquist K, Sundquist J. Cancer incidence in patients with polyglutamine diseases: a population&#x2010;based study in Sweden. Lancet Oncol. 2012;13:642&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">22503213</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman A, Srinivasan V, Barone G, et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer 2011;105:586&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170966</ArticleId><ArticleId IdType="pubmed">21792198</ArticleId></ArticleIdList></Reference><Reference><Citation>Teive HA, Moro A, Moscovich M, et al. Ataxia&#x2010;telangiectasia &#x2010; A historical review and a proposal for a new designation: ATM syndrome. J Neurol Sci 2015;355:3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5161405</ArticleId><ArticleId IdType="pubmed">26050521</ArticleId></ArticleIdList></Reference><Reference><Citation>Damme PV, Goris A, Race V, et al. The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. Eur J Neurol 2010;17:754&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922450</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>